Fibronectin type III repeat based protein scaffolds with alternative binding surfaces
US-9200273-B2 · Dec 1, 2015 · US
Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
US11096998B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11096998-B2 |
| Application number | US-201716323121-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 11, 2017 |
| Priority date | Sep 14, 2016 |
| Publication date | Aug 24, 2021 |
| Grant date | Aug 24, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
First claim
Opening claim text (preview).
We claim: 1. An isolated fibronectin type III (FN3) domain specifically binding to a BCMA, wherein the FN3 domain has the amino acid sequence of one of SEQ ID NOs: 8-44 and 58-145. 2. An isolated fibronectin type III (FN3) domain specifically binding to a BCMA, wherein the FN3 domain has the amino acid sequence of SEQ ID NO: 13.
Assignees
Inventors
Classifications
T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title
Chimeric antigen receptors [CAR] · CPC title
Cancer antigens · CPC title
Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title
CD19 or B4 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11096998B2 cover?
- BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells…
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2878. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).